ALLO Stock News & Catalysts – Allogene Therapeutics

FEATURED

Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease

New

Favorable Early Safety Profile in 18 Patients with No DLTs, IEC-HS, ICANS, GvHD or Grade ≥3 CRSInitial Efficacy Analysis Focused on Skin-Predominant Systemic Sclerosis (SSc/Scleroderma), a Severe Autoimmune Disease with

Summary

Nov 9, 2026, 8:00 AM ·Globe Newswire

RECENT

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-PacificNext ALPHA3

Nov 5, 2026, 4:02 PM ·Globe Newswire

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

Two Invited Presentations Showcase Clinical Progress in Solid Tumors and Allogene's Broader Vision in Oncology and Autoimmune DiseasePreclinical Poster Features Next-Generation DLL3/CD70 Dual CAR T Product Candidate

Nov 3, 2026, 8:00 AM ·Globe Newswire

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ETALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy

Oct 29, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for

Oct 26, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for

Sep 2, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Announces Participation in September Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for

Aug 31, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation

Aug 12, 2026, 4:05 PM ·Globe Newswire

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage

Aug 4, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel’s Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Substantial MRD

Jul 29, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in

Jul 15, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Announces Planned CEO Succession

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of DirectorsZachary Roberts, M.D., Ph.D., EVP,

May 28, 2026, 5:02 PM ·Globe Newswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for

May 26, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel's (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3%

May 13, 2026, 4:02 PM ·Globe Newswire

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology

May 6, 2026, 8:30 AM ·Globe Newswire

Allogene Therapeutics, Inc. ALLO · News